Structure Therapeutics' oral pill aleniglipron achieved 15–16% body weight loss (up to 39 lbs) after 44 weeks in Phase 2, rivaling injectables with better tolerability and no plateau. Phase 3 is planned for 2026—a potential game changer for obesity treatment.
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Structure Therapeutics' (GPCR) experimental obesity pill aleniglipron delivers up to 15.3% weight loss in clinical trials, positioning it as a competitive alternative to Eli Lilly's oral treatment with shares more than doubling on promising Phase 2 results.
